Conjunctivitis, Bacterial: Clinical Trials

7 trials for Conjunctivitis, Bacterial, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Completed 7
Phase 32Completed 2

Follow Conjunctivitis, Bacterial: new trials by email Literature Review of Conjunctivitis, Bacterial trials Research Report on Conjunctivitis, Bacterial

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults
RD03/2016 eye drops, Levofloxacin 0.5% eye drops solution (Oftaquix®) - Conjunctivitis, Bacterial
Phase 2CompletedNTC srl2522021-11-052024-09-27
Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma
IR3535, Permethrin lower dose, Permethrin higher dose - Trachoma
Phase 2CompletedLondon School of Hygiene and Tropical Medicine642019-01-102020-04-08
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
PRO-157, Vigamox, Zymar® - Bacterial Conjunctivitis
Phase 2CompletedLaboratorios Sophia S.A de C.V.1502015-03-012019-05-22
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
Auriclosene Solution 0.3%, Auriclosene Vehicle - Bacterial Conjunctivitis
Phase 2CompletedNovaBay Pharmaceuticals, Inc.2172013-06-012015-05-28
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
Besifloxacin, Vehicle (Placebo) - Bacterial Conjunctivitis
Phase 2 / Phase 3CompletedBausch & Lomb Incorporated4742009-10-012012-03-29
Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis
ISV-403, Vehicle - Bacterial Conjunctivitis
Phase 2CompletedBausch & Lomb Incorporated2702004-12-012015-03-24
Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis
0.5% levofloxacin eye drops - Bacterial Conjunctivitis
Phase 2 / Phase 3CompletedLaser Microsurgery Centre, Poland1192004-09-012007-11-29

Narrower conditions

Conjunctivitis (1)  ·  Trachoma (1)

Broader conditions

Bacterial Infections (7)  ·  Bacterial Infections and Mycoses (7)  ·  Conjunctival Diseases (7)  ·  Eye Diseases (7)  ·  Eye Infections (7)  ·  Eye Infections, Bacterial (7)  ·  Infections (7)  ·  Conjunctivitis (6)  ·  Chlamydia Infections (1)  ·  Chlamydiaceae Infections (1)  ·  Corneal Diseases (1)  ·  Gram-Negative Bacterial Infections (1)

Interventions

Ophthalmic Solutions (2)  ·  besifloxacin (2)  ·  Gatifloxacin (1)  ·  Levofloxacin (1)  ·  Moxifloxacin (1)  ·  NVC-422 (1)  ·  Permethrin (1)  ·  ethyl-3-(N-n-butyl-N-acetyl)aminopropionate (1)  ·  pazufloxacin (1)

Sponsors

Bausch & Lomb Incorporated (2)  ·  Laboratorios Sophia S.A de C.V. (1)  ·  Laser Microsurgery Centre, Poland (1)  ·  London School of Hygiene and Tropical Medicine (1)  ·  NTC srl (1)  ·  NovaBay Pharmaceuticals, Inc. (1)

Countries

United States (2)  ·  Ethiopia (1)  ·  Germany (1)  ·  Italy (1)  ·  Mexico (1)  ·  Poland (1)  ·  Russia (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

David W. Stroman, Ph.D. (1)  ·  Francesco Bandello, Prof. (1)  ·  Jerzy Szaflik, MD,Ph.D. (1)  ·  Leopoldo Baiza, MD (1)  ·  Michael R Paterno, OD (1)  ·  Timothy Comstock, OD (1)

Results publications

PMID 19393842, PMID 20629472, PMID 21397770, PMID 22420526, PMID 22644963, PMID 29602567, PMID 32841261, PMID 35747196